Last updated: February 24, 2026
What is the Drug Represented by NDC 59762-3744?
NDC 59762-3744 corresponds to Viltolarsim, a treatment approved by the FDA for specific cancer indications. Its primary application is in the management of solid tumors with particular genetic mutations, emerging as a targeted therapy option.
Market Size and Demand Drivers
Current Market Landscape
- Estimated global oncology drug market: USD 143.8 billion in 2022, projected to grow at 7.4% annually until 2030 ([1]).
- Target patient population: Approximately 250,000 cases annually worldwide, with an estimated 15-20% exhibiting the genetic mutation responsive to Viltolarsim ([2]).
Key Demand Factors
- Genetic testing adoption: Enhanced screening increases identified eligible patients.
- Competitive landscape: Viltolarsim competes primarily with other kinase inhibitors within the same class.
- Regulatory approvals: Expansions into additional indications can broaden market access.
Market penetration estimates
- Initial penetration phase anticipates capturing 5-10% of eligible patients within 2 years.
- Expansion strategies could increase this to 20-25% over 5 years, contingent on data support and pricing strategies.
Pricing Overview and Trends
Current Pricing
- Average wholesale price (AWP): $12,500 per 28-day treatment cycle.
- Pricing varies by region; in Europe, similar treatments average €10,000 ($11,200) based on exchange rates.
Factors Influencing Price
- Competitive efficacy: Superior outcomes could command higher prices.
- Manufacturing costs: Complexity of production raises baseline costs.
- Reimbursement landscape: Payer policies, formulary placements, and negotiated discounts influence actual net prices.
Price trends and projections
- Historical trend: Similar targeted therapies increased prices by 5-8% annually over the past 3 years ([3]).
- Projected trend: With generic or biosimilar competitors entering, prices may face downward pressure, estimated at 3-5% annual decline in the next 5 years.
Revenue and Sales Projections
| Year |
Market Penetration |
Patients Treated |
Estimated Revenue (USD millions) |
| 2023 |
5% of eligible |
~12,500 |
156 |
| 2025 |
10% of eligible |
~25,000 |
312 |
| 2027 |
15% of eligible |
~37,500 |
468 |
| 2030 |
25% of eligible |
~62,500 |
780 |
Note: These figures assume $12,500 priced treatment cycles, stable demand, and no significant regulatory changes.
Regulatory and Policy Influences
- FDA approval indicates market access in the U.S.
- Pending approvals in Europe and Asia could expand the market.
- Reimbursement policies, especially in the U.S., largely depend on value assessments and payer negotiations, which can significantly alter revenue outcomes.
Market Risks and Challenges
- Competitive drugs with similar efficacy could lead to price erosion.
- Variations in healthcare policies across regions impact access and profitability.
- Patent expiry or biosimilar development may reduce exclusivity and price.
Key Takeaways
- The global oncology market’s growth offers opportunities for Viltolarsim.
- Current pricing remains around $12,500 per cycle, with volatility based on competitive dynamics.
- Market penetration forecasts suggest increasing sales, contingent on regulatory expansion and payer acceptance.
- Price erosion risks are mitigated by high unmet medical needs and targeted therapy positioning.
FAQs
1. How does the market size for NDC 59762-3744 compare to similar drugs?
The current market size for drugs within its class ranges from USD 1.5 to 3 billion annually globally, depending on the specific indication.
2. What factors could significantly impact the price of Viltolarsim?
Regulatory changes, biosimilar competition, patent status, and reimbursement policies hold primary influence over pricing.
3. Are there potential off-label uses that could expand the market?
Yes, if clinical trial data support efficacy in other mutation-driven cancers, off-label use could initially expand the market before formal approval.
4. How do regional differences affect pricing and market access?
Pricing in the U.S. is higher due to different reimbursement structures; European regions often see negotiated discounts, affecting net revenue.
5. What is the likelihood of significant price reductions in coming years?
High likelihood, especially with biosimilar entry and policy shifts towards value-based pricing, projecting a 3-5% annual decline over 5 years.
References
[1] Market Research Future. (2022). Oncology Drugs Market Size, Share & Trends.
[2] Global Cancer Statistics. (2020). International Agency for Research on Cancer.
[3] IMS Health. (2021). Annual Report on Oncology Drug Pricing Trends.
